Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
A Twenty-six Weeks, Open-label Extension Trial to Evaluate Safety and Efficacy of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 21106
Sponsor: Merck Sharp & Dohme LLC
Terminated
This trial was stopped prematurely due to the Sponsor's decision not to continue the development of esmertazapine for this indication.
A PHASE3 clinical study on Dyssomnias and Mental Disorders, this trial is terminated or withdrawn. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 14 data snapshots since 2008. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
14 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jun 2022 [monthly]
Terminated PHASE3
▶ Show 9 earlier versions
-
Mar 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Terminated PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Nov 2018 — Nov 2020 [monthly]
Terminated PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.